CD47 and neoplasm: Strategies for antagonizing CD47 in cancer models have primarily involved the use of anti-CD47 mAbs delivered via intraperitoneal injection, intratumoral injection, or ex vivo coating of tumor cells prior to implantation into mice [158,219,228,237,244,246].